IMPACT OF COMBINED-MODALITY THERAPY ON THE TREATMENT OF ADENOCARCINOMA OF THE COLON

被引:5
|
作者
POSNER, MR
BLEDAY, R
HUBERMAN, M
JESSUP, JM
BUSSE, P
STEELE, G
机构
[1] Department of Medicine, Division of Hematology-Oncology, Harvard Medical School, Boston, Massachusetts
[2] Department of Surgery, New England Deaconess Hospital, Harvard Medical School, Boston, Massachusetts
[3] Joint Center for Radiation Therapy, Harvard Medical School, Boston, Massachusetts
来源
SEMINARS IN SURGICAL ONCOLOGY | 1993年 / 9卷 / 01期
关键词
COLONIC NEOPLASMS; ADJUVANT THERAPY; PROGNOSIS; CHEMOTHERAPY;
D O I
10.1002/ssu.2980090107
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
An emphasis on careful surgical staging of adenocarcinoma of the colon has improved the predictive value of tumor staging systems. As a result of improved staging and carefully conducted randomized clinical trials, adjuvant therapy of locally advanced colon cancer, based on 5-fluorouracil chemotherapy, has been proven to substantially reduce recurrence rates and significantly increase overall survival for selected patients. Improved treatments and schedules are currently being studied in randomized trials and may increase the efficacy of this adjuvant therapy. Radiation therapy has not as yet been integrated into the adjuvant treatment of colon carcinoma. The application of a combined approach of surgery and chemotherapy in selected patients with liver metastases may also improve cure rates and long-term survival. The developing understanding of molecular determinants for the biological behavior of these cancers will increase the opportunities to identify, on the one hand, those patients who will benefit from specific therapies, and, on the other hand, new therapeutic strategies and treatments. (C) 1993 Wiley-Liss, Inc.
引用
收藏
页码:33 / 38
页数:6
相关论文
共 50 条
  • [1] Combined-modality treatment for operable-pancreatic adenocarcinoma
    Pisters, Peter W. T.
    Wolff, Robert A.
    Crane, Christopher H.
    Evans, Douglas B.
    ONCOLOGY-NEW YORK, 2005, 19 (03): : 393 - +
  • [2] COMBINED-MODALITY THERAPY IN THE TREATMENT OF ESOPHAGEAL CANCER
    ILSON, DH
    KELSEN, DP
    SEMINARS IN ONCOLOGY, 1994, 21 (04) : 493 - 507
  • [3] EFFECTIVENESS OF CHEMOTHERAPY FOR ADVANCED ADENOCARCINOMA OF THE PANCREAS IN COMBINED-MODALITY THERAPY
    KATO, H
    WAKASUGI, H
    YOKOTA, M
    FURUKAWA, M
    MUKUTA, T
    YAMADA, Y
    FUNAKOSHI, A
    INTERNAL MEDICINE, 1994, 33 (03) : 142 - 146
  • [4] SUCCESSFUL TREATMENT OF A CARDIAC ANGIOSARCOMA WITH COMBINED-MODALITY THERAPY
    BAAY, P
    KARWANDE, SV
    KUSHNER, JP
    OLSEN, S
    RENLUND, DG
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 1994, 13 (05): : 923 - 925
  • [5] Combined-modality staging for localized adenocarcinoma of the prostate
    D'Amico, AV
    ONCOLOGY-NEW YORK, 2001, 15 (08): : 1049 - 1059
  • [6] CERVICAL METASTASES OF OCCULT ORIGIN - THE IMPACT OF COMBINED-MODALITY THERAPY
    DAVIDSON, BJ
    SPIRO, RH
    PATEL, S
    PATEL, K
    SHAH, JP
    AMERICAN JOURNAL OF SURGERY, 1994, 168 (05): : 395 - 399
  • [7] The role of UFT in combined-modality therapy
    Blanke, CD
    Teng, M
    Choy, H
    ONCOLOGY-NEW YORK, 1999, 13 (10): : 47 - 54
  • [8] Docetaxel and radiation as combined-modality therapy
    Kim, ES
    Khuri, FR
    ONCOLOGY-NEW YORK, 2002, 16 (06): : 97 - 105
  • [9] COMBINED-MODALITY THERAPY OF ESOPHAGEAL CANCER
    KELSEN, D
    BAINS, M
    HILARIS, B
    MARTINI, N
    SEMINARS IN ONCOLOGY, 1984, 11 (02) : 169 - 177
  • [10] Combined-modality therapy in gastrointestinal cancers
    Thomas, Charles Richard, Jr.
    Bond, Theo
    COLORECTAL CANCER, 2013, 2 (01) : 27 - 30